Humimmun

Humimmun is a biotechnology company focused on the discovery and development of novel humanized monoclonal antibodies for the treatment of inflammatory and autoimmune diseases. The company leverages its proprietary antibody discovery platform to identify high-affinity candidates targeting key cytokines such as IL-17 and IL-23. Humimmun's pipeline is currently in the pre-clinical stage, with a focus on indications including psoriasis and inflammatory bowel disease. By utilizing advanced protein engineering, the company aims to develop therapies with improved efficacy and safety profiles compared to existing biologics. Humimmun operates primarily as a research-driven entity, seeking to advance its programs through strategic partnerships and internal development.